{
    "nctId": "NCT02324387",
    "briefTitle": "Tc99m Sestamibi Molecular Breast Imaging",
    "officialTitle": "Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 96,
    "primaryOutcomeMeasure": "Detection of Treatment Response using Molecular Breast Imaging (MBI) plus Tc99m sestamibi",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female of 18 years and older of any race\n2. Has biopsy-proven invasive breast cancer (BI-RADS 6) and scheduled for neoadjuvant chemotherapy (NAC).\n3. Newly diagnosed biopsy proven locoregional invasive breast cancer at MD Anderson Cancer Center, or referred to MD Anderson for treatment after initial radiologic (mammographic, sonographic, etc.) exams at an outside institution in whom NAC is planned.\n4. Patients with stage T1 or greater (T1-T4), nodal involvement (N0 - N3), without metastasis (M0) invasive breast cancer, including patients with inflammatory breast cancer.\n5. Patients who agree to sign an informed consent to undergo MBI\n\nExclusion Criteria:\n\n1. Is under 18 years of age\n2. Is pregnant (confirmed by the patient as Imaging Clinic standard of care) or nursing mother\n3. Has lesions involving chest wall\n4. Has known allergy to Tc99m sestamibi",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}